Rising levels of antibiotic resistance dictate that new antibiotics with novel modes of action must be found. Here, we investigated the mode of action of a novel antibiotic that is a member of a family of synthetic DNA minor groove binding (MGB) molecules. MGB-BP-3 has successfully completed a Phase II clinical trial in humans as an orally administered drug for the treatment of chronic Clostridioides (Clostridium) difficile infections, where it outperformed the existing benchmark (vancomycin). MGB-BP-3 is active against a variety of Gram-positive pathogens including Staphylococcus aureus, which was used as the model for this study. The transcriptomic response of S. aureus to MGB-BP-3 identified downregulated promoters. DNase I and permanganate footprinting demonstrated binding to essential SigA promoters and the inhibition of promoter isomerisation by RNA polymerase holoenzyme. Promoters controlling DNA replication and peptidoglycan biosynthesis are amongst those affected by MGB-BP-3. Thus, MGB-BP-3 binds to and inhibits multiple essential promoters on the S. aureus chromosome, suggesting that evolution of resistance by drug target mutation should be unlikely. In confirmation, laboratory-directed evolution against sub-inhibitory concentrations of MGB-BP-3 resulted in no resistance whereas resistance to the single target RNA-polymerase inhibitor rifampicin arose rapidly.
Lysophosphatidic acid (LPA) occurs naturally in inflammatory exudates and has previously been shown to increase the susceptibility of Pseudomonas aeruginosa to β-lactam antibiotics whilst concomitantly reducing accumulation of the virulence factors pyoverdine and elastase. Here it is demonstrated that LPA can also exert inhibitory effects upon pyocyanin production in P. aeruginosa , as well as influencing susceptibility to a wide range of chemically diverse non β-lactam antimicrobials. Most strikingly, LPA markedly antagonizes the effect of the polycationic antibiotics colistin and tobramycin at a concentration of 250 µg ml−1 whilst conversely enhancing their efficacy at the lower concentration of 8.65 µg ml−1, approximating the maximal physiological concentrations found in inflammatory exudates. Transcriptomic responses of the virulent strain UCBPP-PA14 to LPA were analysed using RNA-sequencing along with BioLog phenoarrays and whole cell assays in attempts to delineate possible mechanisms underlying these effects. The results strongly suggest involvement of LPA-induced carbon catabolite repression together with outer-membrane (OM) stress responses whilst raising questions about the effect of LPA upon other P. aeruginosa virulence factors including type III secretion. This could have clinical relevance as it suggests that endogenous LPA may, at concentrations found in vivo, differentially modulate antibiotic susceptibility of P. aeruginosa whilst simultaneously regulating expression of virulence factors, thereby influencing host–pathogen interactions during infection. The possibility of applying exogenous LPA locally as an enhancer of select antibiotics merits further investigation.
There is an urgent need for new antimicrobials due to constantly advancing antimicrobial resistance. Here, we worked with environmental samples from diverse habitats including different savannah and forest soils, volcanic caves, and termite mounds and assessed their microbial communities for the potential of biosynthesis of secondary metabolites. We analysed and compared microbial composition by applying the QIIME2 pipeline to 16S rRNA gene data. We focused on the abundance of Actinobacteria and Streptomyces as they are important producers of antimicrobials. Out of the samples analysed, the highest abundance of Actinobacteria was found in termite mound and volcanic cave samples. Moreover, the termite mound samples also had the highest abundance of Streptomyces. When comparing microbial composition, soil samples and termite mound samples each formed their own clusters, but volcanic cave samples appeared more dispersed. We assessed the antimicrobial potential of a subset of samples by analysing metagenomic data to predict biosynthetic gene clusters (BGCs) using antiSMASH5.2.0, which resulted in over 800 hits per sample. This number was narrowed down by evaluating identified BGCs based on antimicrobial potential, completeness, size, presence/absence of regulatory and transport-related genes, and dissimilarity with known BGCs. This resulted in an average of 20 BGCs per sample. These BGCs will be subjected to further sequence-based analyses before attempting heterologous expression. Following successful expression, antimicrobial potential will be assessed by screening for growth inhibition of multidrug resistant E.coli strains and the ESKAPE pathogens.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.